Peter S. Linsley
83Patents
32h-index
89Co-inventors
91Inventor score
Filing activity: Dec 21, 1984 → Jun 11, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5844095A | CTLA4 Ig fusion proteins | Chemistry; Metallurgy | 219 | Expired |
| US5434131A | Chimeric CTLA4 receptor and methods for its use | Emerging Cross-Sectional Technologies | 194 | Expired |
| US7171311B2 | Methods of assigning treatment to breast cancer patients | Chemistry; Metallurgy | 182 | Expired |
| US6132992A | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell | Physics | 172 | Expired |
| US5977318A | CTLA4 receptor and uses thereof | Emerging Cross-Sectional Technologies | 151 | Expired |
| US7595387B2 | Modified polynucleotides for reducing off-target effects in RNA interference | Chemistry; Metallurgy | 138 | Expired |
| US5637481A | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell | Physics | 130 | Expired |
| US5580756A | B7IG fusion protein | Emerging Cross-Sectional Technologies | 130 | Expired |
| US5521288A | CD28IG fusion protein | Emerging Cross-Sectional Technologies | 118 | Expired |
| US5770197A | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules | Emerging Cross-Sectional Technologies | 111 | Expired |
| US7514209B2 | Diagnosis and prognosis of breast cancer patients | Emerging Cross-Sectional Technologies | 104 | Expired |
| US5851795A | Soluble CTLA4 molecules and uses thereof | Emerging Cross-Sectional Technologies | 99 | Expired |
| US5885796A | CTLA4 receptor and uses thereof | Emerging Cross-Sectional Technologies | 98 | Expired |
| US7013221B1 | Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays | Physics | 98 | Expired |
| US5773253A | MYPPPY variants of CTL A4 and uses thereof | Chemistry; Metallurgy | 95 | Expired |
| US5916560A | Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith | Chemistry; Metallurgy | 91 | Expired |
| US5968510A | CTLA4 receptor and uses thereof | Emerging Cross-Sectional Technologies | 88 | Expired |
| US6271002A | RNA amplification method | Chemistry; Metallurgy | 86 | Expired |
| US6623940B1 | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell | Physics | 80 | Expired |
| US6090914A | CTLA4/CD28Ig hybrid fusion proteins and uses thereof | Chemistry; Metallurgy | 79 | Expired |
| US5709859A | Mixed specificity fusion proteins | Emerging Cross-Sectional Technologies | 75 | Expired |
| US7304033B2 | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | Chemistry; Metallurgy | 66 | Expired |
| US5885579A | CTLA4 receptor and uses thereof | Emerging Cross-Sectional Technologies | 64 | Expired |
| US5849876A | Hybridomas producing monoclonal antibodies to new mucin epitopes | Human Necessities | 56 | Expired |
| US6641809B1 | Method of regulating cellular processes mediated by B7 and CD28 | Emerging Cross-Sectional Technologies | 55 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.